Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Long-Term Investments (2021 - 2023)

AVITA Medical filings provide 3 years of Long-Term Investments readings, the most recent being $2.8 million for Q2 2023.

  • On a quarterly basis, Long-Term Investments fell 59.16% to $2.8 million in Q2 2023 year-over-year; TTM through Jun 2023 was $2.8 million, a 59.16% decrease, with the full-year FY2022 number at $6.9 million, down 64.81% from a year prior.
  • Long-Term Investments hit $2.8 million in Q2 2023 for AVITA Medical, down from $4.2 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $19.8 million in Q3 2021 to a low of $2.8 million in Q2 2023.
  • Median Long-Term Investments over the past 3 years was $6.8 million (2022), compared with a mean of $9.5 million.
  • Biggest five-year swings in Long-Term Investments: plummeted 79.74% in 2022 and later tumbled 59.16% in 2023.
  • AVITA Medical's Long-Term Investments stood at $19.7 million in 2021, then tumbled by 64.81% to $6.9 million in 2022, then crashed by 60.26% to $2.8 million in 2023.
  • The last three reported values for Long-Term Investments were $2.8 million (Q2 2023), $4.2 million (Q1 2023), and $6.9 million (Q4 2022) per Business Quant data.